Survival is not longer if the tumour size is bigger; if it has distributed to two lobes of the liver. But the chance of survival is good if the tumour size is small in one lobe and the patient is youn...

Many new treatments are being pioneered here, many new approaches and of course the prevalence of liver disease in the Asian Pacific and in particular hepatocellular carcinoma are larger than they are...

When we are talking about re-treating patients with established anti-viral resistance, I think we will really look at approaches. For example Lamivudine resistance when we add in Adefovir we find it ...

Well I think the traditional approach has been to have a baseline serum HBV. DNA level and then you have to monitor the patient at some regular interval, probably initially every three months with rep...

Next year yes the APASL conference will be held in Beijing. I have talked with Professor Jia (Ji-Dong Jia) and also We need to do a lot of things, not only including the organization of the conferenc...